查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541059

2024-2032 年偏头痛药物市场报告（依治疗类型、药物类型、给药途径、配销通路和地区）

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球偏头痛药物市场规模达42亿美元。全球偏头痛药物市场的成长在很大程度上受到偏头痛同化程度的提高、治疗过程知识的不断扩大、基于CGRP 的药物等疗法的开发、预防性治疗的推广以及新兴市场不断增加的扩张机会的推动。

偏头痛药物市场分析：

主要市场驱动因素：全球偏头痛发病率的增加是偏头痛药物市场份额大幅成长的关键因素。对这种疾病的认识的提高和治疗选择的增加推动了对偏头痛药物的高需求。此外，主要参与者专注于开发 CGRP 治疗等更健康治疗方法的研发活动的兴起，正在对市场趋势产生积极影响。

主要市场趋势：偏头痛药物市场趋势包括日益关注预防性药物和治疗途径的改进。市场参与者的策略行动，例如新产品发布和合作伙伴关係，增加了该领域的疗法和创新的数量。

地理趋势：由于该地区主要参与者的存在、支持性报销政策以及对精准医疗的关注，北美在偏头痛药物市场上占据主导地位。偏头痛的普遍增加以及对改善患者治疗结果的日益关注是促进该地区市场扩张的其他因素。

竞争格局：偏头痛药物产业的一些主要市场参与者包括雅培实验室、艾尔建公司（艾伯维公司）、安进公司、阿斯特捷利康公司、博士健康公司（原Valeant 製药公司）、卫材有限公司、礼来公司、远藤国际公司、葛兰素史克公司、强生公司、默克公司、诺华公司、辉瑞公司、赛诺菲公司、梯瓦製药工业有限公司等。

挑战与机会：市场面临药物副作用的出现、严格的规则、规章等挑战。此外，机会在于不断扩张的亚洲国家，这些国家的偏头痛发病率居高不下，而且新的、更有效的中世纪疗法也正在开发中。

偏头痛药物市场趋势：

提高认识和诊断

人们对偏头痛及其极度致残类型的认识的增加增加了偏头痛药物的需求。就其盛行率而言，游客仍然未被诊断或治疗不足。政府卫生机构（包括疾病管制与预防中心 (CDC)）的主要作用是向人们提供有关偏头痛的指导，从而导致寻求医疗支持的疾病人数增加。此外，随着越来越多的人意识到有效治疗的必要性，他们也促进了对治疗的需求，从而推动了市场的成长。根据 CDC 的数据，在美国约有 20% 的女性和 9% 的男性患有偏头痛。它占人口的很大一部分。人们越来越认识到偏头痛是一个重要的健康问题，这促使偏头痛患者和医疗保健专业人员寻找最有前景的偏头痛治疗方法。

药物开发的进展

科学和药物开发的不断进步推动了偏头痛药物市场的收入。在製药领域，针对偏头痛患者的创新疗法的研发是重要的工作量之一。这涉及使用功效、安全性和给药方式优越的药物，包括使用新的给药系统或药物製剂。根据美国国立卫生研究院 (NIH) 的资料，目前正在进行超过 100 项与偏头痛治疗相关的临床试验，这更证实了研究界正在紧接着寻找治疗方法的观点。每一项发现都开启了一个新的市场，为患者提供了不同的选择，治疗方法也变得更好，改善了偏头痛患者的生活条件。

医疗保健支出增加

全球医疗保健支出的不断增长正在创造积极的偏头痛药物市场前景。政府和私人机构正在将越来越多的资金集中在预防和减少偏头痛等疾病上，这些疾病已知会立即影响医疗保健系统和社会。根据世界卫生组织（WHO）的数据，全球医疗保健支出一直呈现持续扩张趋势，主要是为了因应慢性病管理状况。因此，这些人更容易获得医疗保健行业的服务和治疗，从而增加了对偏头痛药物的需求。这种模式在偏头痛越来越普遍的新兴市场最为突出，这反过来又为製药公司提供治疗偏头痛症状的疗法和干预措施提供了具体途径。

偏头痛药物市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据治疗类型、药物类型、给药途径和配销通路对市场进行了分类。

按治疗类型细分：

流产治疗

预防性治疗

预防性治疗占大部分市场份额

该报告根据治疗类型对市场进行了详细的细分和分析。这包括流产治疗和预防性治疗。报告称，预防性治疗占最大部分。

预防性药物在偏头痛药物市场中占据主导地位，因为它已被证明有助于减少偏头痛发作的频率和强度，从而提高患者的生活品质。根据美国国立卫生研究院 (NIH) 的报告，美国 38% 的偏头痛患者正在寻求预防性治疗，但只有极少数人接受了治疗。前者强调预防方法的连贯未满足的必要性。由于偏头痛持续存在，而且最好的治疗药物是预防性药物，因此医生和患者越来越多地使用预防性药物来治疗急性病例。因此，这种成长趋势需要将预防方法作为偏头痛管理的核心。

按药物类型细分：

曲普坦类

麦角生物碱

非类固醇抗发炎药

乙酰胆碱抑制剂/神经毒素

迪坦斯

CGRP 单株抗体

其他的

曲普坦类药物占据业界最大份额

报告还根据药物类型对市场进行了详细的细分和分析。这包括曲坦类、麦角生物碱、NSAID、乙酰胆碱抑制剂/神经毒素、ditans、CGRP mAb 等。报告称，曲坦类药物占据最大的市场份额。

根据偏头痛药物市场预测，曲坦类药物在市场上处于领先地位，因为偏头痛药物能够快速缓解偏头痛症状，特别是头痛、颈部疼痛、噁心以及对光和噪音敏感。例如，根据美国国家神经疾病和中风研究所 (NINDS) 的报告，曲坦类药物在美国处方率最高，是美国医生最常用于治疗急性偏头痛的药物类别。它们透过刺激血管中的交感纤维和阻碍疼痛信号传递到大脑来发挥作用。在美国，超过 20% 的女性和 9% 的男性有偏头痛经历，因此在曲坦类药物等有效的急性治疗方面仍然存在严重的住院护理缺口。它们的日益普及和医疗保健提供者的广泛接受证明了它们在治疗急性偏头痛药物市场中的地位，让患者相信它们缓解疼痛的能力。

依给药途径分类：

口服

可注射

其他的

口服代表领先的市场

该报告根据给药途径对市场进行了详细的细分和分析。这包括口服、注射和其他。根据该报告，口服占最大部分。

口服给药途径推动了偏头痛药物的市场价值，因为口服药物使用方便且易于使用，患者可以在家中或旅途中自行进行治疗，无需医疗监督。根据美国国家神经疾病和中风研究所 (NINDS) 的数据，口服药物是医疗保健提供者最常用的偏头痛治疗方法。与其他途径相比，其口服製剂还可以更快起效，有助于缓解急性偏头痛患者的症状。由于美国 20% 的女性和 9% 的男性患有偏头痛，因此对口服治疗的需求增加。这些治疗的可及性和有效性使得口服药物途径的主导地位适用于偏头痛药物市场。

按配销通路划分：

医院药房

零售药局

其他的

报告还提供了基于配销通路的详细市场细分和分析。这包括医院药房、零售药房等。

医院药房以医院为基础，设在医院内，为住院患者和门诊患者提供药物和药物服务。在偏头痛药物市场中，医院药局在为急性偏头痛治疗患者提供急诊室或门诊诊所方面发挥着至关重要的作用。他们库存的药物种类较多，包括曲坦类药物和其他专门用于治疗偏头痛的药物。这确保了急性偏头痛患者的快速取得和给药。

零售药局是位于商业和住宅区的药局，向大众提供处方药和非处方药。除了零售药局之外，需要急性和预防性治疗的偏头痛患者也会到这些药局取得药物，因为这是一个关键的护理点。他们为患者提供咨询和支持，这对于正确使用药物和严格遵循治疗方案非常重要。由于零售药局提供了便利，它们透过照顾偏头痛患者（甚至在周围不同的社区）而成为偏头痛药物分销和供应的关键参与者。

按地区划分：

北美洲

美国

加拿大

亚太地区

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的偏头痛药物市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是偏头痛药物的最大市场。

北美由于该地区疾病患病率高而占据市场主导地位，而该地区拥有强大的医疗基础设施和高额医疗支出，构成了市场成长的支柱。根据美国国家神经疾病和中风研究所 (NINDS) 的资料，每 10 个美国人就有 1 个患有偏头痛。除此之外，北美有几家大型製药公司，主要从事抗偏头痛药物的开发，因此建立了一个有利于研究和产品开发的环境。此外，美国食品药物管理局（FDA）等政府机构为确保偏头痛治疗药物的审批速度所做的努力也有助于该地区的市场扩张。因此，这些力量使北美保持在全球偏头痛药物行业的顶尖水平。

竞争格局：

偏头痛药物市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。偏头痛药物产业的一些主要市场参与者包括雅培实验室、艾尔建公司（艾伯维公司）、安进公司、阿斯特捷利康公司、博士健康公司（原Valeant 製药公司）、卫材有限公司、礼来公司和公司、远藤国际公司、葛兰素史克公司、强生公司、默克公司、诺华公司、辉瑞公司、赛诺菲公司和梯瓦製药工业有限公司。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

偏头痛药物市场的主要参与者不断致力于研发和商业化阶段，旨在满足偏头痛患者的需求。安进(Amgen)、礼来(Eli Lilly) 和梯瓦製药(Teva Pharmaceutical Industries) 等製药公司正在推广尖端疗法，例如降钙素基因相关胜肽(CGRP) 抑制剂和gepants，用于治疗和预防急性偏头痛。例如，根据美国国立卫生研究院 (NIH) 的偏头痛药物市场研究报告，这些公司目前正在招募参与者进行试验，目的是评估药物的安全性和有效性。制定这些各自的措施、提高人们对偏头痛的整体认识以及获得适当的治疗也是这些公司的优先事项之一。

偏头痛药物市场新闻：

2022 年 2 月，Biohaven Pharmaceutical 和辉瑞公司在亚太地区进行的一项 3 期临床试验显示了积极的顶线结果，该试验旨在确定 rimegepant 在偏头痛治疗中的有效性。这项研究证明了 Rimegepant 对妊娠偏头痛及其相关症状的有效和安全应用。 Rimegepant 是一种针对降钙素基因相关胜肽 (CGRP) 受体的小分子，已被证明可以有效快速结束急性偏头痛发作。这些资料确定了亚洲国家地区偏头痛患者治疗可近性的重要一步，这可能会导致 Rimegepant 获得监管部门的批准。

2022年1月，BioDelivery Sciences推出了偏头痛治疗领域的先锋产品Elyxyb（塞来昔布口服溶液）。它是美国食品药物管理局 (FDA) 批准的高效成人即用型口服溶液之一，可快速治疗有先兆或无先兆的急性偏头痛发作。 Elyxyb 的配方为液体形式，这使得患者可以快速、轻鬆地使用它，从而为他们提供了一种有效的方法来阻止偏头痛症状。这款新产品的推出体现了该公司对偏头痛患者的努力和关注，过去偏头痛患者的治疗方法不足，现在这款新产品为他们提供了显着改善生活品质的机会。

本报告回答的关键问题：

  • 迄今为止，全球偏头痛药物市场表现如何，未来几年将如何表现？
  • 全球偏头痛药物市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球偏头痛药物市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的偏头痛药物市场？
  • 根据治疗类型的市场划分是怎样的？
  • 偏头痛药物市场上最具吸引力的治疗类型是什么？
  • 根据药物类型分類的市场是怎么样的？
  • 偏头痛药物市场中哪种药物最有吸引力？
  • 根据给药途径，市场的分化为何？
  • 偏头痛药物市场上哪种给药途径最具吸引力？
  • 基于配销通路的市场区隔是什么？
  • 偏头痛药物市场哪个配销通路最具吸引力？
  • 市场竞争结构如何？
  • 全球偏头痛药物市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 迄今为止，全球偏头痛药物市场表现如何，未来几年将如何表现？
  • 全球偏头痛药物市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球偏头痛药物市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的偏头痛药物市场？
  • 根据治疗类型的市场划分是怎样的？
  • 偏头痛药物市场上最具吸引力的治疗类型是什么？
  • 根据药物类型分類的市场是怎么样的？
  • 偏头痛药物市场中哪种药物最有吸引力？
  • 根据给药途径，市场的分化为何？
  • 偏头痛药物市场上哪种给药途径最具吸引力？
  • 基于配销通路的市场区隔是什么？
  • 偏头痛药物市场哪个配销通路最具吸引力？
  • 市场竞争结构如何？
  • 全球偏头痛药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球偏头痛药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依治疗类型

  • 流产治疗
    • 市场趋势
    • 市场预测
  • 预防性治疗
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按药物类型

  • 曲普坦类
    • 市场趋势
    • 市场预测
  • 麦角生物碱
    • 市场趋势
    • 市场预测
  • 非类固醇抗发炎药
    • 市场趋势
    • 市场预测
  • 乙酰胆碱抑制剂/神经毒素
    • 市场趋势
    • 市场预测
  • 迪坦斯
    • 市场趋势
    • 市场预测
  • CGRP 单株抗体
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依管理途径

  • 口服
    • 市场趋势
    • 市场预测
  • 可注射
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售药局
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Allergan Plc (Abbvie Inc.)
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
Product Code: SR112024A2543

The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets.

Migraine Drugs Market Analysis:

Major Market Drivers: The increasing incidence of migraines worldwide is the crucial factor for the significant growth in migraine drugs market share. The rise in recognition of the disease and the option for treatment is fueling the high demand for migraine medicines. Moreover, the rise of research and development activities by the main actors focusing on the development of healthier treatments such as CGRP treatment is having a positive effect on the market trend.

Key Market Trends: The migraine drug market trends include the increasing focus on preventive medications and the improvements in treatment pathways. Strategic actions of market players, for instance, new product launches and partnerships, have escalated the number of therapies and innovations in the field.

Geographical Trends: North America dominates the migraine drugs market due to the presence of key players, supportive reimbursement policies, and a focus on precision medicine in the region. The widespread rise of migraines and the growing focus on improving patient outcomes are other factors that contribute to the expansion of the market in this region.

Competitive Landscape: Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, among many others.

Challenges and Opportunities: The market faces challenges including the emergence of the side effects of medicines and the strict rules and regulations. Moreover, opportunities lie in expanding Asian countries, where the rate of migraine stays high and the development of new, more effective medieval treatments.

Migraine Drugs Market Trends:

Increasing Awareness and Diagnosis

The increase in the perception of migraine headaches and their extremely disabling type of outcome has augmented the migraine drugs demand. As for its prevalence, visitors continue to be undiagnosed or undertreated. The primary role of government health agencies, including, for example, the Centers for Disease Control and Prevention (CDC), is to instruct people about migraines resulting in the increased number of sick individuals who seek medical support. Additionally, as more people become aware of the necessity for efficient treatments, they also contribute to the demand for treatments, which fuels the market growth. According to the CDC, there is approximately 20% of women and 9% of man who are suffering from migraines in the United States. It is a significant percentage of the population. This increasing appreciation of migraines as a significant health matter promotes both migraine patients and healthcare professionals to search for the most prospective migraine treatment variation.

Advancements in Drug Development

Ongoing improvement in scientific and drug development drives the migraine drugs market revenue. In the pharmaceutical sector, the research and development of innovative treatments for migraine sufferers present one of the important workloads. This involves the use of medications that are superior in efficacy, safety, and administration modes, including the use of new delivery systems or drug formulations. According to the National Institutes of Health (NIH) data, over 100 clinical trials associated with migraine treatment are currently ongoing, which only strengthens the view that the research community is hot on the heels in search of the treatment. Every discovery opens a new market niche in which different options are becoming available for patients, and the treatment becomes better, improving the living conditions of migraineurs people.

Rising Healthcare Expenditure

The rising healthcare expenditure around the world is creating a positive migraine drug market outlook. The governments and the private methods are concentrating more and more funds on the prevention and reduction of diseases like migraines which are known to imminently affect healthcare systems and society. As per the World Health Organization (WHO), worldwide healthcare spending has been experiencing a constant trend of expansion, largely to deal with chronic disease management conditions. As a result, these people gain easier access to the healthcare industry services and cures, escalating the demand for migraine medicine. This pattern is the most prominent in the emerging markets, in which migraines are getting more widespread and this in turn provides specific avenues for pharmaceutical companies in terms of the therapies and interventions they provide for managing the symptoms of migraines.

Migraine Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, drug type, route of administration, and distribution channel.

Breakup by Treatment Type:

Abortive Treatment

Preventive Treatment

Preventive treatment accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes abortive treatment and preventive treatment. According to the report, preventive treatment represented the largest segment.

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

Triptans

Ergot Alkaloids

NSAIDs

Acetylcholine Inhibitors/ Neurotoxins

Ditans

CGRP mAbs

Others

Triptans hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug type have also been provided in the report. This includes triptans, ergot alkaloids, NSAIDs, acetylcholine inhibitors/neurotoxins, ditans, CGRP mAbs, and others. According to the report, triptans accounted for the largest market share.

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

Oral

Injectable

Others

Oral represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, injectable, and others. According to the report, oral represented the largest segment.

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

Hospital-Based Pharmacies

Retail Pharmacies

Others

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital-based pharmacies, retail pharmacies, and others.

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region's market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies.

Migraine Drugs Market News:

In February 2022, Biohaven Pharmaceutical and Pfizer revealed positive top-line results with a Phase 3 clinical trial, which was conducted in the Asia-Pacific region and aimed to determine rimegepant's effectiveness in the option of migraine treatment. This study demonstrated effective and safe rimegepant application for pregnant migraine and its associated symptoms. Rimegepant, a tiny molecule targeting calcitonin gene-related peptide (CGRP) receptors, proved to be effective in ending acute migraine attacks speedily. The data ascertains a momentous step in migraine sufferers' therapeutic accessibility progress in the Asian national region, which could potentially lead to regulatory approval of rimegepant.

In January 2022, BioDelivery Sciences introduced Elyxyb (celecoxib oral solution) which is pioneering in the field of migraine treatment. It is among the highly effective adult ready-to-use oral solutions approved by the Food and Drug Administration (FDA) as a quick remedy for acute migraine attacks either with or without aura. Elyxyb's formulation comes in a liquid form, which makes its application fast and easy for the patients, thus providing them with an efficient approach to stop the symptoms of migraines. The introduction of this novel product reflects the company's effort and concern toward migraine patients, who had inadequate treatment methods at their disposal in the past, now this new product offers them the chance to improve their quality of life significantly.

Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global migraine drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global migraine drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive migraine drugs market?
  • What is the breakup of the market based on the treatment type?
  • Which is the most attractive treatment type in the migraine drugs market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the migraine drugs market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the migraine drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the migraine drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global migraine drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players